X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
1. Acid, Orotic
2. Orotate, Potassium
3. Orotate, Sodium
4. Orotate, Zinc
5. Potassium Orotate
6. Sodium Orotate
7. Zinc Orotate
1. 65-86-1
2. 6-carboxyuracil
3. Oropur
4. Orodin
5. Orotonin
6. Orotyl
7. Orotonsan
8. Vitamin B13
9. Whey Factor
10. Oroturic
11. 2,6-dioxo-1,2,3,6-tetrahydropyrimidine-4-carboxylic Acid
12. Uracil-6-carboxylic Acid
13. Animal Galactose Factor
14. 6-uracilcarboxylic Acid
15. 2,6-dihydroxypyrimidine-4-carboxylic Acid
16. Molkensaeure
17. Orotsaeure
18. Orotate
19. Uracil-6-carbosaeure
20. 4-pyrimidinecarboxylic Acid, 1,2,3,6-tetrahydro-2,6-dioxo-
21. 2,6-dihydroxy-4-pyrimidinecarboxylic Acid
22. Orotsaeure [german]
23. Acidum Oroticum
24. Acide Orotique
25. Acido Orotico
26. Acide Orotique [french]
27. Acido Orotico [spanish]
28. Acidum Oroticum [latin]
29. Nsc 9791
30. Acide Orotique [inn-french]
31. Acido Orotico [inn-spanish]
32. Acidum Oroticum [inn-latin]
33. 2,4-dioxo-1h-pyrimidine-6-carboxylic Acid
34. Ccris 3929
35. Orotic Acid (6-carboxyuracil)
36. Hsdb 6377
37. Ai3-25478
38. 1,2,3,6-tetrahydro-2,6-dioxopyrimidin-4-carbonsaeure
39. 1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidecarboxylic Acid
40. 6-carboxy-2,4-dihydroxypyrimidine
41. Nsc9791
42. Nsc-9791
43. Poe (12) Tall Oil
44. Mfcd00006027
45. 1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinecarboxylic Acid
46. 61791-00-2
47. Chebi:16742
48. Orotic Acid, Anhydrous
49. Orotic Acid (jan)
50. 61h4t033e5
51. Ncgc00091357-01
52. 1,2,3,4-tetrahydro-2,6-dioxopyrimidine-4-carboxylic Acid
53. Dsstox_cid_5814
54. Orotic Acid [jan]
55. Dsstox_rid_77933
56. Dsstox_gsid_25814
57. Oro
58. Oroticacid
59. Orotic Acid [inn:jan]
60. Cas-65-86-1
61. Orotic Acid (van)
62. Nsc627082
63. Einecs 200-619-8
64. Orotsaure
65. Orotic-acid
66. Orotic Acid [inn:ban:jan]
67. Unii-61h4t033e5
68. Uracil-6-carboxylate
69. Orotic Acid Anhydrous
70. Orotic Acid (8ci)
71. 2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-carboxylic Acid
72. Orotic-acid-
73. Orotic Acid [mi]
74. Bmse000283
75. Orotic Acid [inn]
76. Orotic Acid [hsdb]
77. Orotic Acid [inci]
78. Schembl20865
79. Orotic Acid [mart.]
80. Mls006011823
81. Orotic Acid(6-carboxyuracil)
82. Orotic Acid (van) (8ci)
83. Orotic Acid [who-dd]
84. Gtpl4690
85. Chembl1235017
86. Dtxsid0025814
87. Ethoxylated Tall Oil Fatty Acids
88. Amy4076
89. Hms3264k19
90. Hms3651i20
91. Pharmakon1600-01504525
92. Bcp09063
93. Hy-n0157
94. Zinc1408068
95. Tox21_111121
96. Tox21_201104
97. Bbl013050
98. Nsc758903
99. S2336
100. Stk301771
101. Stk629991
102. Akos000119689
103. Akos004115502
104. Tox21_111121_1
105. Ccg-213952
106. Db02262
107. Nsc-758903
108. Sb55525
109. Ncgc00091357-02
110. Ncgc00188943-01
111. Ncgc00188943-03
112. Ncgc00188943-04
113. Ncgc00258656-01
114. Smr001550463
115. Sy006030
116. Ts-00078
117. 2,6-dihydroxy-pyrimidin-4-carboxylic Acid
118. Sbi-0207042.p001
119. 2,6-dihydroxy-pyrimidine-4-carboxylic Acid
120. Db-073669
121. 4-pyrimidinecarboxylic Acid, 2,6-dihydroxy-
122. A8909
123. B1147
124. Bb 0242405
125. Ft-0603612
126. Ft-0648914
127. O0065
128. Orotic Acid, >=98% (titration), Anhydrous
129. Sw219707-1
130. C00295
131. D00055
132. D70614
133. Ab00373897_03
134. Ab-323/25048164
135. Q425536
136. Sr-01000872754
137. Sr-01000872754-1
138. W-104782
139. F2191-0093
140. 2,6-dioxo-1,2,3,6-tetrahydro-pyrimidine-4-ca Rboxylic Acid
141. 37c71c07-0d69-452c-8c54-7d01be02c146
142. 4-pyrimidinecarboxylic Acid, 1,2,3,6-tetrahydro-2,6-dioxo- (9ci)
| Molecular Weight | 156.10 g/mol |
|---|---|
| Molecular Formula | C5H4N2O4 |
| XLogP3 | -1.4 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 1 |
| Exact Mass | 156.01710661 g/mol |
| Monoisotopic Mass | 156.01710661 g/mol |
| Topological Polar Surface Area | 95.5 Ų |
| Heavy Atom Count | 11 |
| Formal Charge | 0 |
| Complexity | 268 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Uricosuric
O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. 13th Edition, Whitehouse Station, NJ: Merck and Co., Inc., 2001., p. 1230
This study deals with the potential therapeutic effect of orotic acid (OA) and Mg Orotate (MgO) on myocardial degeneration and the development of congestive heart failure in cardiomyopathic (CM) hamsters of the UM-X7.1 line. Two major age groups (group I, < 30 days and group II, > 180 days old) were used in these experiments, which lasted 30 and 50 days, respectively; the orotic salts were incorporated (10%) into Purina Lab Chow given ad libitum. Macroscopic and microscopic assessment of pathologic changes together with ECG recordings revealed that MgO treatment significantly reduces myocardial damage, especially the severity of calcific changes. ECG recordings clearly demonstrated a significant shortening of QTc and PR intervals, resulting in partial electrical stabilization of failing hearts, with a significant delay in systemic congestive changes. The prevention of heart lesions was less evident in animals receiving OA, but both preparations proved to be equally efficient in prolonging survival of the CM hamsters.
PMID:9794093 Jasmin G, Proschek L; Cardiovasc Drugs Ther 12 (Suppl 2): 189-95 (1998)
... Three studies were performed: (1) The time course of changes in tissue and plasma concentrations of pyrimidine compounds was examined in unoperated rats after the administration of 100 mg/kg OA. (2) Rats were given OA (30 mg/kg/d) for 2 days after experimental infarction, and tissue and plasma pyrimidine concentrations were examined; the hearts were removed for perfusion in the isolated working rat heart model (37 degrees C), subjected to 30 minutes of global ischemia, and recovery of function was assessed. AN content was assessed in the noninfarcted myocardium before and after ischemia. Isolated hearts were subjected to 30 minutes of hypoxic perfusion and the effect of adding 17 microM uridine to the perfusate was examined. Study 1 showed that OA administration produced an increase in hepatic uridine and cytidine, followed by increased plasma uridine and cytidine (cytidine, +55%, P < 0.001; uridine, +124%, P = 0.011). Myocardial uracil nucleotides increased temporarily after 4 hours (+21%, P < 0.01). In infarcted hearts after 2 days of OA administration, there were no significant changes in myocardial uracil or cytosine nucleotides or total RNA. Infarction significantly reduced functional recovery after global ischemia (sham = 62%; infarct = 26% of preischemic level; P < 0.05). OA improved the recovery of preischemic function by 133% (P < 0.05) in infarcted, but not sham-operated, hearts. Preischemic ATP and total adenine nucleotides (TAN) were decreased in the surviving myocardium of infarcted hearts (ATP reduced from 21.7 +/- 0.8 to 14.7 +/- 0.7 mumol/g dry wt, P < 0.001; TAN decreased from 30.3 +/- 0.8 to 22.4 +/- 1.1 mumol/g dry wt, P < 0.001). OA treatment prevented these reductions. Study 3 showed that uridine improved myocardial ATP and TAN levels, and decreased purine loss in hypoxic hearts. The increased AN levels were accompanied by evidence of enhancement of anerobic glycolysis.
PMID:9794090 Rosenfeldt FL et al; Cardiovasc Drugs Ther 12 (Suppl. 2): 159-70 (1998)
[14C]Orotic acid was rapidly distributed in blood after both i.p. and s.c. injection but was not completely absorbed from the peritoneal cavity until 20 min after injection. S.c. injection should be an acceptable alternative to i.p. injection although the incorporation into the liver acid soluble- and RNA-fractions was somewhat delayed after the s.c. injection.
PMID:858350 Engelbrecht C et al; Experientia 33 (3): 302-4 (1977)
... The aim of this work was to investigate whether orotate is differently metabolized in gut and in liver thus explaining the lack of effect on the intestinal lipoproteins secretion. Multienzyme complex (complex U) was found in appreciable amounts in rat, mouse and rabbit livers; the intestinal mucosa of the two last species contains a much lower level of multienzyme complex whereas in rat intestine its activity cannot be detected. Indeed, radioactive aspartate and orotate were not incorporated into intestinal cells RNA. The absence of orotate metabolisation by lack of orotate phosphoribosyltransferase and orotidine 5'-phosphate decarboxylase activity in rat intestine would explain why this organ, in contrast to the liver, is protected against disturbances of nucleotide metabolism and lipoproteins secretion induced by orotic-acid-supplemented diets.
PMID:7297564 Raisonnier A et al; Eur J Biochem 118 (3): 565-9 (1981)
Market Place
